ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för oltipraz. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

16 träffar

Bibliografisk träff 2013-10-31

miR-125b transcriptionally increased by Nrf2 inhibits AhR repressor, which protects kidney from cisplatin-induced injury.

Joo MS, Lee CG, Koo JH, Kim SG.

Cell Death Dis · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/cddis.2013.427

Bibliografisk träff 2013-08-23

Deleterious effect of oltipraz on extrahepatic cholestasis in bile duct-ligated mice.

Weerachayaphorn J, Luo Y, Mennone A, Soroka CJ, Harry K, Boyer JL.

J Hepatol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.jhep.2013.08.015

Bibliografisk träff 2013-08-01

The nuclear factor erythroid 2-related factor 2 activator oltipraz attenuates chronic hypoxia-induced cardiopulmonary alterations in mice.

Eba S, Hoshikawa Y, Moriguchi T, Mitsuishi Y, Satoh H, Ishida K, Watanabe T, Shimizu T, Shimokawa H, Okada Y, Yamamoto M, Kondo T.

Am J Respir Cell Mol Biol · research support, non-u.s. gov't; journal article · DOI 10.1165/rcmb.2011-0396oc

Bibliografisk träff 2013-04-16

Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model.

Shimozono R, Asaoka Y, Yoshizawa Y, Aoki T, Noda H, Yamada M, Kaino M, Mochizuki H.

Mol Pharmacol · journal article · DOI 10.1124/mol.112.084269

Bibliografisk träff 2012-07-20

Multi-layer polymeric implants for sustained release of chemopreventives.

Aqil F, Jeyabalan J, Kausar H, Bansal SS, Sharma RJ, Singh IP, Vadhanam MV, Gupta RC.

Cancer Lett · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.canlet.2012.07.017

Bibliografisk träff 2012-01-04

Hypoxia-inducible factor-1α inhibition by a pyrrolopyrazine metabolite of oltipraz as a consequence of microRNAs 199a-5p and 20a induction.

Kang SG, Lee WH, Lee YH, Lee YS, Kim SG.

Carcinogenesis · journal article · DOI 10.1093/carcin/bgr320

Bibliografisk träff 2011-06-25

Quantification of oltipraz using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study in rat plasma.

Lee JH, Lim H, Kim DG, Park DH, Woo YA, Noh HJ, Jin QR, Lee KR, Lee GW, Kim CY.

J Pharm Biomed Anal · journal article · DOI 10.1016/j.jpba.2011.06.014

Bibliografisk träff 2011-03-14

Oltipraz therapy in patients with liver fibrosis or cirrhosis: a randomized, double-blind, placebo-controlled phase II trial.

Kim SG, Kim YM, Choi JY, Han JY, Jang JW, Cho SH, Um SH, Chon CY, Lee DH, Jang JJ, Yu E, Lee YS.

J Pharm Pharmacol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.2042-7158.2011.01259.x

Bibliografisk träff 2010-12-16

Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 [corrected](NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice.

Yu Z, Shao W, Chiang Y, Foltz W, Zhang Z, Ling W, Fantus IG, Jin T.

Diabetologia · research support, non-u.s. gov't; journal article · DOI 10.1007/s00125-010-2001-8

Bibliografisk träff 2010-07-21

Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: relationship with suppression of circulating TGF-beta1.

Kim SG, Kim YM, Choi YH, Lee MG, Choi JY, Han JY, Cho SH, Jang JW, Um SH, Chon CY, Lee DH, Jang JJ, Yu ES, Lee YS.

Clin Pharmacol Ther · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1038/clpt.2010.89

Bibliografisk träff 2010-06-30

Inactivation of protein tyrosine phosphatases by oltipraz and other cancer chemopreventive 1,2-dithiole-3-thiones.

Bhattacharyya S, Zhou H, Seiner DR, Gates KS.

Bioorg Med Chem · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.bmc.2010.06.084

Bibliografisk träff 2010-02-01

Antioxidant and mitochondrial protective effects of oxidized metabolites of oltipraz.

Choi SH, Kim YM, Lee JM, Kim SG.

Expert Opin Drug Metab Toxicol · research support, non-u.s. gov't; review; journal article · DOI 10.1517/17425250903427972

Bibliografisk träff 2009-10-12

Involvement of pregnane X receptor in the regulation of CYP2B6 gene expression by oltipraz in human hepatocytes.

Piton A, Rauch C, Langouet S, Guillouzo A, Morel F.

Toxicol In Vitro · research support, non-u.s. gov't; journal article · DOI 10.1016/j.tiv.2009.09.025

Bibliografisk träff 1993-01-01

Oltipraz: a laboratory and clinical review.

Benson AB.

J Cell Biochem Suppl · review; journal article · DOI 10.1002/jcb.240531041

Bibliografisk träff 1984-04-01

[Epidemiologic study of 2 foci of Schistosoma mansoni bilharziasis in Togo (Lama Kara and Kpalimé). Comparative efficacy of oltipraz (RP 35972)].

Lapierre J, Amedome A, Tourte-Schaefer C, Agbo K, Kotor T, Faurant C, Ancelle T, Heyer F, Dupouy-Camet J.

Med Trop (Mars) · comparative study; journal article

Bibliografisk träff 1982-03-01

[The treatment of Schistosomiasis mansoni with RP 35972 (Oltipraz). Preliminary results (author's transl)].

Cerf P, Moyroud J, Coulanges P.

Bull Soc Pathol Exot Filiales · journal article